Search

Your search keyword '"Courtright, Jay"' showing total 22 results
Start Over Author "Courtright, Jay"
22 results on '"Courtright, Jay"'

1. OUTREACH: phase 2 study of lisocabtagene maraleucel as outpatient or inpatient treatment at community sites for R/R LBCL

Author

Linhares, Yuliya, Freytes, Cesar O., Cherry, Mohamad, Bachier, Carlos, Maris, Michael, Hoda, Daanish, Varela, Juan C., Bellomo, Courtney, Cross, Scott, Essell, James, Fanning, Suzanne, Terebelo, Howard, Yimer, Habte, Courtright, Jay, Sharman, Jeff P., Kostic, Ana, Vedal, Min, Ogasawara, Ken, Avilion, Ariel, Espinola, Ricardo, Yuan, Brenda, and Mattar, Bassam

Published
2024
Full Text
View/download PDF

2. Lenvatinib plus Pembrolizumab Following Immune Checkpoint Inhibitor Treatment in Patients with Metastatic Clear Cell Renal Cell Carcinoma: Results from Study 111/KEYNOTE-146

Author

Lee, Chung-Han, primary, Yogesh Shah, Amishi, additional, Rao, Arpit, additional, Taylor, Matthew H., additional, Di Simone, Christopher, additional, Hsieh, James J., additional, Pinto, Alvaro, additional, Gironés Sarrió, Regina, additional, Lee Cohn, Allen, additional, Asim Bilen, Mehmet, additional, Gunnestad Ribe, Sara, additional, Krohn Tennøe, Øyvind, additional, Richards, Donald, additional, Sweis, Randy F., additional, Courtright, Jay, additional, Heinrich, Daniel, additional, Perini, Rodolfo, additional, Kubiak, Peter, additional, Bock, Daena, additional, Okpara, Chinyere E., additional, and Motzer, Robert J., additional

Published
2024
Full Text
View/download PDF

3. Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study

Author

Lee, Chung-Han, Shah, Amishi Yogesh, Rasco, Drew, Rao, Arpit, Taylor, Matthew H, Di Simone, Christopher, Hsieh, James J, Pinto, Alvaro, Shaffer, David R, Girones Sarrio, Regina, Cohn, Allen Lee, Vogelzang, Nicholas J, Bilen, Mehmet Asim, Gunnestad Ribe, Sara, Goksel, Musaberk, Tennøe, Øyvind Krohn, Richards, Donald, Sweis, Randy F, Courtright, Jay, Heinrich, Daniel, Jain, Sharad, Wu, Jane, Schmidt, Emmett V, Perini, Rodolfo F, Kubiak, Peter, Okpara, Chinyere E, Smith, Alan D, and Motzer, Robert J

Published
2021
Full Text
View/download PDF

4. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

Author

Cascallar, Diana Vera, Varela, Mirta, Lazzaro, Mauricio Fernandez, Kaen, Diego Lucas, Gatica, Gabriela, Flores, David Hugo, Falco, Agustin, Molina, Matias, Van Aelst, Filip, Vulsteke, Christof, Sautois, Brieuc, Machiels, Jean-Pascal, Schallier, Denis, Brust, Leandro, Rapatoni, Liane, Azevedo, Sergio J, Marinho, Gisele, Soares, Joao Paulo Holanda, Dzik, Carlos, Almeida Silva, Jamile, Fay, Andre Poisl, Gingerich, Joel, Fradet, Yves, Ferrario, Cristiano, Potvin, Kylea, Vanhuyse, Marie, Abdelsalam, Mahmoud, Cheng, Susanna, Caglevic, Christian, Reyes, Felipe, Leal, Jose Luis, Francisco, Francisco, Ibanez, Carolina, Joly, Florence, Laguerre, Brigitte, Ladoire, Sylvain, Flechon, Aude, Topart, Delphine, Huillard, Olivier, Oudard, Stéphane, Gross-Goupil, Marine, Culine, Stephane, Loriot, Yohann, Gravis, Gwenaelle, Reichardt, Peter, Retz, Margitta, Herden, Jan, Pfister, David, Ohlman, Carsten, Stoeckle, Michael, Wirth, Manfred, Lorch, Anja, Niegisch, Guenter, Goebell, Peter J, Boegemann, Martin, Merseburger, Axel, Gakis, Georgios, Bedke, Jens, Neisius, Andreas, Thomas, Christian, Hoefner, Thomas, Telekes, Andras, Kosa, Judit Erzsebet, Revesz, Janos, Bodoky, Gyorgy, Csoszi, Tibor, Csejtei, Andras, Geczi, Lajos, Ruzsa, Agnes, Kolonics, Zsuzsanna, Erfan, Jozsef, McDermott, Ray, Bambury, Richard, Sella, Avishay, Frank, Stephen Jay, Kejzman, Daniel, Goldman, Olesya, Rosenbaum, Eli, Peer, Avivit, Berger, Raanan, Rouvinov, Keren, Sarid, David, Fukasawa, Satoshi, Arai, Gaku, Yamaguchi, Akito, Yokomizo, Akira, Takayama, Tatsuya, Kinoshita, Hidefumi, Kikuchi, Eiji, Mizuno, Ryuichi, Fujii, Yasuhisa, Sassa, Naoto, Matsukawa, Yoshihisa, Fujimoto, Kiyohide, Matsubara, Nobuaki, Tanikawa, Toshiki, Tomita, Yoshihiko, Nishimura, Kazuo, Tsujihata, Masao, Oyama, Masafumi, Masumori, Naoya, Kanayama, Hiroomi, Takano, Toshimi, Miura, Yuji, Miyazaki, Jun, Joraku, Akira, Kimura, Tomokazu, Yamamoto, Yoshiaki, Kobayashi, Kazuki, De Wit, Ronald, Aarts, Maureen, Gerritsen, Winald, Los, Maartje, Beerepoot, Laurens, Izmailov, Adel, Gorelov, Sergey Igorevich, Alekseev, Boris Yakovlevich, Semenov, Andrey, Kostorov, Vladimir Anatolyevich, Alekseev, Sergey M, Zyryanov, Alexander, Oschepkov, Vasiliy Nikolaevich, Shidin, Vladimir Aleksandrovich, Vladimirov, Vladimir Ivanovich, Gafanov, Rustem Airatovich, Karlov, Petr Alexandrovich, Anderson, David Brian, Shepherd, Lucinda, Cohen, Graham Lawrence, Rapoport, Bernardo Louis, Ruff, Paul, Lee, Nari, Bae, Woo Kyun, Lee, Hyo Jin, Herranz, Urbano Anido, Rodriguez-Vida, Alejo, Morales Barrera, Rafael, Grande, Enrique, Alonso Gordoa, Teresa, Guma Padro, Josep, Gauna, Daniel Castellano, Arranz, Jose Angel, Munoz Langa, Jose, Sarrio, Regina Girones, Montesa Pino, Alvaro, Juan Fita, Maria Jose, Su, Yu-Li, Lin, Yung-Chang, Su, Wen-Pin, Shen, Ying-Chun, Chang, Yen-Hwa, Huang, Yi-Hsiu, Sriuranpong, Virote, Chansriwong, Phichai, Srimuninnimit, Vichien, Danchaivijitr, Pongwut, Abali, Huseyin, Yavuz, Sinan, Ozyilkan, Ozgur, Sendur, Mehmet Ali Nahit, Ekenel, Meltem, Ozguroglu, Mustafa, Arslan, Cagatay, Gunduz, Seyda, Ozdogan, Mustafa, Birtle, Alison, Powles, Thomas, Huddart, Robert, de Santis, Maria, Zarkar, Anjali, Evans, Linda, Hussain, Syed, DiSimone, Christopher, Muina, Antonio F, Schlegel, Peter, Jhangiani, Haresh S, Harrison, Michael, Slater, Dennis E, Wright, David, Percent, Ivor J, Lin, Jianqing, Hwang, Clara, Mamtani, Ronac, Gupta, Sumati, Bajaj, Madhuri, Galamaga, Robert, Eklund, John, Wallace, James, Shtivelband, Mikhail, Suh, Jason Jung-Gon, Burhani, Nafisa, Eadens, Matthew, Gunturu, Krishna, Burgess, Earle, Wong, John, Chaudhry, Arvind, Van Veldhuizen, Peter, Graff, Stephanie, Thomas, Christian A, Schnadig, Ian D, Carneiro, Benedito, Hussain, Maha, Morgans, Alicia, Fitzharris, John T, Oliff, Ira A, Vuky, Jacqueline, Hauke, Ralph, Baron, Ari, Joshi, Monika, Bolemon, Britt H, Jiang, Peter, Mega, Anthony E, Markus, Maurice, Pfanzelter, Nicklas, Lawler, William Eyre, Cobb, Patrick Wayne, Courtright, Jay G, Jain, Sharad, Doshi, Gurjyot, Gunuganti, Vijay K, Sartor, Oliver Alton, Cole, Scott W, Babiker, Hani, Uchio, Edward M, Drakaki, Alexandra, Mannuel, Heather D, Alva, Ajjai, Guancial, Elizabeth, Fung, Chunkit, Charles, Anthony, Amato, Robert J, Arriaga, Yull, Bowman, Isaac, Ades, Steven, Dreicer, Robert, Yu, Evan, Quinn, David I, Fleming, Mark, Csőszi, Tibor, Özgüroğlu, Mustafa, Géczi, Lajos, Cheng, Susanna Y-S, Oudard, Stephane, Fléchon, Aude, Yu, Evan Y, Nam, Kijoeng, Imai, Kentaro, and Homet Moreno, Blanca

Published
2021
Full Text
View/download PDF

5. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA

Author

Liu, Minetta C., Oxnard, Geoffrey R., Klein, Eric A., Smith, David, Richards, Donald, Yeatman, Timothy J., Cohn, Allen L., Lapham, Rosanna, Clement, Jessica, Parker, Alexander S., Tummala, Mohan K., McIntyre, Kristi, Sekeres, Mikkael A., Bryce, Alan H., Siegel, Robert, Wang, Xuezhong, Cosgrove, David P., Abu-Rustum, Nadeem R., Trent, Jonathan, Thiel, David D., Becerra, Carlos, Agrawal, Manish, Garbo, Lawrence E., Giguere, Jeffrey K., Michels, Ross M., Harris, Ronald P., Richey, Stephen L., McCarthy, Timothy A., Waterhouse, David M., Couch, Fergus J., Wilks, Sharon T., Krie, Amy K., Balaraman, Rama, Restrepo, Alvaro, Meshad, Michael W., Rieger-Christ, Kimberly, Sullivan, Travis, Lee, Christine M., Greenwald, Daniel R., Oh, William, Tsao, Che-Kai, Fleshner, Neil, Kennecke, Hagen F., Khalil, Maged F., Spigel, David R., Manhas, Atisha P., Ulrich, Brian K., Kovoor, Philip A., Stokoe, Christopher, Courtright, Jay G., Yimer, Habte A., Larson, Timothy G., Swanton, Charles, Seiden, Michael V., Cummings, Steven R., Absalan, Farnaz, Alexander, Gregory, Allen, Brian, Amini, Hamed, Aravanis, Alexander M., Bagaria, Siddhartha, Bazargan, Leila, Beausang, John F., Berman, Jennifer, Betts, Craig, Blocker, Alexander, Bredno, Joerg, Calef, Robert, Cann, Gordon, Carter, Jeremy, Chang, Christopher, Chawla, Hemanshi, Chen, Xiaoji, Chien, Tom C., Civello, Daniel, Davydov, Konstantin, Demas, Vasiliki, Desai, Mohini, Dong, Zhao, Fayzullina, Saniya, Fields, Alexander P., Filippova, Darya, Freese, Peter, Fung, Eric T., Gnerre, Sante, Gross, Samuel, Halks-Miller, Meredith, Hall, Megan P., Hartman, Anne-Renee, Hou, Chenlu, Hubbell, Earl, Hunkapiller, Nathan, Jagadeesh, Karthik, Jamshidi, Arash, Jiang, Roger, Jung, Byoungsok, Kim, TaeHyung, Klausner, Richard D., Kurtzman, Kathryn N., Lee, Mark, Lin, Wendy, Lipson, Jafi, Liu, Hai, Liu, Qinwen, Lopatin, Margarita, Maddala, Tara, Maher, M. Cyrus, Melton, Collin, Mich, Andrea, Nautiyal, Shivani, Newman, Jonathan, Newman, Joshua, Nicula, Virgil, Nicolaou, Cosmos, Nikolic, Ongjen, Pan, Wenying, Patel, Shilpen, Prins, Sarah A., Rava, Richard, Ronaghi, Neda, Sakarya, Onur, Satya, Ravi Vijaya, Schellenberger, Jan, Scott, Eric, Sehnert, Amy J., Shaknovich, Rita, Shanmugam, Avinash, Shashidhar, K.C., Shen, Ling, Shenoy, Archana, Shojaee, Seyedmehdi, Singh, Pranav, Steffen, Kristan K., Tang, Susan, Toung, Jonathan M., Valouev, Anton, Venn, Oliver, Williams, Richard T., Wu, Tony, Xu, Hui H., Yakym, Christopher, Yang, Xiao, Yecies, Jessica, Yip, Alexander S., Youngren, Jack, Yue, Jeanne, Zhang, Jingyang, Zhang, Lily, Zhang, Lori (Quan), Zhang, Nan, Curtis, Christina, Berry, Donald A., Liu, M.C., Oxnard, G.R., Klein, E.A., Swanton, C., and Seiden, M.V.

Published
2020
Full Text
View/download PDF

6. POSTER: CT-045 Primary Results From OUTREACH: A Phase II Study of Lisocabtagene Maraleucel (Liso-Cel) Administered in the Community Setting as Outpatient or Inpatient Treatment in Patients With Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Author

Linhares, Yuliya, primary, Freytes, Cesar, additional, Cherry, Mohamad, additional, Bachier, Carlos, additional, Maris, Michael, additional, Hoda, Daanish, additional, Varela, Juan C., additional, Bellomo, Courtney, additional, Cross, Scott, additional, Essell, James, additional, Fanning, Suzanne, additional, Terebelo, Howard, additional, Yimer, Habte, additional, Courtright, Jay, additional, Sharman, Jeff P., additional, Kostic, Ana, additional, Vedal, Min, additional, Ogasawara, Ken, additional, Avilion, Ariel, additional, Espinola, Ricardo, additional, Yuan, Brenda, additional, and Mattar, Bassam, additional

Published
2023
Full Text
View/download PDF

7. CT-045 Primary Results From OUTREACH: A Phase II Study of Lisocabtagene Maraleucel (Liso-Cel) Administered in the Community Setting as Outpatient or Inpatient Treatment in Patients With Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Author

Linhares, Yuliya, primary, Freytes, Cesar, additional, Cherry, Mohamad, additional, Bachier, Carlos, additional, Maris, Michael, additional, Hoda, Daanish, additional, Varela, Juan C., additional, Bellomo, Courtney, additional, Cross, Scott, additional, Essell, James, additional, Fanning, Suzanne, additional, Terebelo, Howard, additional, Yimer, Habte, additional, Courtright, Jay, additional, Sharman, Jeff P., additional, Kostic, Ana, additional, Vedal, Min, additional, Ogasawara, Ken, additional, Avilion, Ariel, additional, Espinola, Ricardo, additional, Yuan, Brenda, additional, and Mattar, Bassam, additional

Published
2023
Full Text
View/download PDF

8. Results from Outreach: A Phase 2 Study of Lisocabtagene Maraleucel (Liso-cel) Administered As Outpatient (Outpt) or Inpatient (Inpt) Treatment in the Community/Nonuniversity Setting in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Author

Linhares, Yuliya, primary, Freytes, Cesar, additional, Cherry, Mohamad, additional, Bachier, Carlos, additional, Maris, Michael, additional, Hoda, Daanish, additional, Varela, Juan Carlos, additional, Bellomo, Courtney, additional, Cross, Scott, additional, Essell, James, additional, Fanning, Suzanne, additional, Terebelo, Howard, additional, Yimer, Habte, additional, Courtright, Jay, additional, Sharman, Jeff P., additional, Vedal, Min, additional, Mailley, Connor, additional, Espinola, Ricardo, additional, and Mattar, Bassam, additional

Published
2022
Full Text
View/download PDF

10. Debulking before Initiation of Venetoclax Therapy in Untreated Patients with Chronic Lymphocytic Leukemia: Results from a Phase 3b Study

Author

Flinn, Ian W., primary, Andorsky, David, additional, Melear, Jason, additional, Manda, Sudhir, additional, Anz, Bertrand, additional, Kolibaba, Kathryn, additional, Yimer, Habte, additional, Burke, John M., additional, Fanning, Suzanne, additional, Courtright, Jay, additional, Islas-Ohlmayer, Miguel, additional, Kambhampati, Suman, additional, Vizkelety, Tamas, additional, Pesko, John, additional, Chyla, Brenda, additional, Jiang, Dingfeng, additional, and Sharman, Jeff P., additional

Published
2021
Full Text
View/download PDF

11. Outreach: Results from a Phase 2 Study of Lisocabtagene Maraleucel (liso-cel) Administered As Inpatient (Inpt) or Outpatient (Outpt) Treatment in the Nonuniversity Setting in Patients (Pts) with R/R Large B-Cell Lymphoma (LBCL)

Author

Godwin, John E., primary, Mattar, Bassam, additional, Maris, Michael, additional, Bachier, Carlos, additional, Stevens, Don, additional, Hoda, Daanish, additional, Varela, Juan C., additional, Cherry, Mohamad, additional, Fanning, Suzanne, additional, Essell, James, additional, Yimer, Habte, additional, Courtright, Jay, additional, Sharman, Jeff P., additional, Espinola, Ricardo, additional, Mailley, Connor, additional, Avilion, Ariel, additional, Ogasawara, Ken, additional, Ou, San-San, additional, and Shaughnessy, Paul, additional

Published
2021
Full Text
View/download PDF

12. Lenvatinib in Combination With Pembrolizumab in Patients with Treatment-Naïve and Treatment-Experienced Metastatic Renal Cell Carcinoma: Results From a Phase 1b/2 Study

Author

Lee, Chung-Han, Shah, Amishi Yogesh, Rasco, Drew, Rao, Arpit, Taylor, Matthew H., Di Simone, Christopher, Hsieh, James J., Pinto, Alvaro, Shaffer, David R., Sarrio, Regina Girones, Cohn, Allen Lee, Vogelzang, Nicholas J., Bilen, Mehmet Asim, Ribe, Sara Gunnestad, Goksel, Musaberk, Tennøe, Øyvind Krohn, Richards, Donald, Sweis, Randy F., Courtright, Jay, Heinrich, Daniel, Jain, Sharad, Wu, Jane, Schmidt, Emmett V., Perini, Rodolfo F., Kubiak, Peter, Okpara, Chinyere E., Smith, Alan D., and Motzer, Robert J.

Subjects
Male, Time Factors, Phenylurea Compounds, Middle Aged, Antibodies, Monoclonal, Humanized, Article, Kidney Neoplasms, United States, Europe, Antineoplastic Agents, Immunological, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols, Quinolines, Humans, Female, Carcinoma, Renal Cell, Immune Checkpoint Inhibitors, Protein Kinase Inhibitors, Aged
Abstract

Despite advances in the first-line treatment of metastatic renal cell carcinoma (RCC), there is an unmet need for options to address disease progression during or after treatment with immune checkpoint inhibitors (ICIs). Pembrolizumab and lenvatinib are active as monotherapies in RCC; thus, we aimed to evaluate the combination of lenvatinib plus pembrolizumab in these patients.We report results of the metastatic RCC cohort from an open-label phase 1b/2 study of lenvatinib plus pembrolizumab in patients aged at least 18 years with selected solid tumours and an Eastern Cooperative Oncology Group performance status of 0-1. Oral lenvatinib at 20 mg was given once daily along with intravenous pembrolizumab at 200 mg once every 3 weeks. Patients remained on study drug treatment until disease progression, development of unacceptable toxicity, or withdrawal of consent. Efficacy was analysed in patients with clear cell metastatic RCC receiving study drug by previous therapy grouping: treatment naive, previously treated ICI naive (previously treated with at least one line of therapy but not with an anti-PD-1 or anti-PD-L1 ICI), and ICI pretreated (ie, anti-PD-1 or anti-PD-L1) patients. Safety was analysed in all enrolled and treated patients. The primary endpoint was the objective response rate at week 24 per immune-related Response Evaluation Criteria In Solid Tumors (irRECIST) by investigator assessment. This trial is registered with ClinicalTrials.gov (NCT02501096) and with the EU Clinical Trials Register (EudraCT2017-000300-26), and is closed to new participants.Between July 21, 2015, and Oct 16, 2019, 145 patients were enrolled in the study. Two patients had non-clear cell RCC and were excluded from the efficacy analysis (one in the treatment-naive group and one in the ICI-pretreated group); thus, the population evaluated for efficacy comprised 143 patients (n=22 in the treatment-naive group, n=17 in the previously treated ICI-naive group, and n=104 in the ICI-pretreated group). All 145 enrolled patients were included in the safety analysis. The median follow-up was 19·8 months (IQR 14·3-28·4). The number of patients with an objective response at week 24 by irRECIST was 16 (72·7%, 95% CI 49·8-89·3) of 22 treatment-naive patients, seven (41·2%, 18·4-67·1) of 17 previously treated ICI-naive patients, and 58 (55·8%, 45·7-65·5) of 104 ICI-pretreated patients. Of 145 patients, 82 (57%) had grade 3 treatment-related adverse events and ten (7%) had grade 4 treatment-related adverse events. The most common grade 3 treatment-related adverse event was hypertension (30 [21%] of 145 patients). Treatment-related serious adverse events occurred in 36 (25%) patients, and there were three treatment-related deaths (upper gastrointestinal haemorrhage, sudden death, and pneumonia).Lenvatinib plus pembrolizumab showed encouraging antitumour activity and a manageable safety profile and might be an option for post-ICI treatment of metastatic RCC.Eisai and Merck SharpDohme.

Published
2021

13. Outcomes of Treatment with the Chimeric Antigen Receptor (CAR) T Cell Therapy Lisocabtagene Maraleucel (liso-cel) in the Nonuniversity Setting: Initial Results from the Outreach Study

Author

Godwin, John E., Freytes, Cesar O., Maris, Michael, Stevens, Don A., Hoda, Daanish, Mattar, Bassam, Varela, Juan C., Cherry, Mohamad, Essell, James, Courtright, Jay, Fanning, Suzanne R., Yimer, Habte A., Trede, Nikolaus S., Youssef, Marina, Lymp, James, and Bachier, Carlos

Published
2020
Full Text
View/download PDF

14. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

Author

Powles, Thomas, primary, Csőszi, Tibor, additional, Özgüroğlu, Mustafa, additional, Matsubara, Nobuaki, additional, Géczi, Lajos, additional, Cheng, Susanna Y-S, additional, Fradet, Yves, additional, Oudard, Stephane, additional, Vulsteke, Christof, additional, Morales Barrera, Rafael, additional, Fléchon, Aude, additional, Gunduz, Seyda, additional, Loriot, Yohann, additional, Rodriguez-Vida, Alejo, additional, Mamtani, Ronac, additional, Yu, Evan Y, additional, Nam, Kijoeng, additional, Imai, Kentaro, additional, Homet Moreno, Blanca, additional, Alva, Ajjai, additional, Cascallar, Diana Vera, additional, Varela, Mirta, additional, Lazzaro, Mauricio Fernandez, additional, Kaen, Diego Lucas, additional, Gatica, Gabriela, additional, Flores, David Hugo, additional, Falco, Agustin, additional, Molina, Matias, additional, Van Aelst, Filip, additional, Sautois, Brieuc, additional, Machiels, Jean-Pascal, additional, Schallier, Denis, additional, Brust, Leandro, additional, Rapatoni, Liane, additional, Azevedo, Sergio J, additional, Marinho, Gisele, additional, Soares, Joao Paulo Holanda, additional, Dzik, Carlos, additional, Almeida Silva, Jamile, additional, Fay, Andre Poisl, additional, Gingerich, Joel, additional, Ferrario, Cristiano, additional, Potvin, Kylea, additional, Vanhuyse, Marie, additional, Abdelsalam, Mahmoud, additional, Cheng, Susanna, additional, Caglevic, Christian, additional, Reyes, Felipe, additional, Leal, Jose Luis, additional, Francisco, Francisco, additional, Ibanez, Carolina, additional, Joly, Florence, additional, Laguerre, Brigitte, additional, Ladoire, Sylvain, additional, Flechon, Aude, additional, Topart, Delphine, additional, Huillard, Olivier, additional, Oudard, Stéphane, additional, Gross-Goupil, Marine, additional, Culine, Stephane, additional, Gravis, Gwenaelle, additional, Reichardt, Peter, additional, Retz, Margitta, additional, Herden, Jan, additional, Pfister, David, additional, Ohlman, Carsten, additional, Stoeckle, Michael, additional, Wirth, Manfred, additional, Lorch, Anja, additional, Niegisch, Guenter, additional, Goebell, Peter J, additional, Boegemann, Martin, additional, Merseburger, Axel, additional, Gakis, Georgios, additional, Bedke, Jens, additional, Neisius, Andreas, additional, Thomas, Christian, additional, Hoefner, Thomas, additional, Telekes, Andras, additional, Kosa, Judit Erzsebet, additional, Revesz, Janos, additional, Bodoky, Gyorgy, additional, Csoszi, Tibor, additional, Csejtei, Andras, additional, Geczi, Lajos, additional, Ruzsa, Agnes, additional, Kolonics, Zsuzsanna, additional, Erfan, Jozsef, additional, McDermott, Ray, additional, Bambury, Richard, additional, Sella, Avishay, additional, Frank, Stephen Jay, additional, Kejzman, Daniel, additional, Goldman, Olesya, additional, Rosenbaum, Eli, additional, Peer, Avivit, additional, Berger, Raanan, additional, Rouvinov, Keren, additional, Sarid, David, additional, Fukasawa, Satoshi, additional, Arai, Gaku, additional, Yamaguchi, Akito, additional, Yokomizo, Akira, additional, Takayama, Tatsuya, additional, Kinoshita, Hidefumi, additional, Kikuchi, Eiji, additional, Mizuno, Ryuichi, additional, Fujii, Yasuhisa, additional, Sassa, Naoto, additional, Matsukawa, Yoshihisa, additional, Fujimoto, Kiyohide, additional, Tanikawa, Toshiki, additional, Tomita, Yoshihiko, additional, Nishimura, Kazuo, additional, Tsujihata, Masao, additional, Oyama, Masafumi, additional, Masumori, Naoya, additional, Kanayama, Hiroomi, additional, Takano, Toshimi, additional, Miura, Yuji, additional, Miyazaki, Jun, additional, Joraku, Akira, additional, Kimura, Tomokazu, additional, Yamamoto, Yoshiaki, additional, Kobayashi, Kazuki, additional, De Wit, Ronald, additional, Aarts, Maureen, additional, Gerritsen, Winald, additional, Los, Maartje, additional, Beerepoot, Laurens, additional, Izmailov, Adel, additional, Gorelov, Sergey Igorevich, additional, Alekseev, Boris Yakovlevich, additional, Semenov, Andrey, additional, Kostorov, Vladimir Anatolyevich, additional, Alekseev, Sergey M, additional, Zyryanov, Alexander, additional, Oschepkov, Vasiliy Nikolaevich, additional, Shidin, Vladimir Aleksandrovich, additional, Vladimirov, Vladimir Ivanovich, additional, Gafanov, Rustem Airatovich, additional, Karlov, Petr Alexandrovich, additional, Anderson, David Brian, additional, Shepherd, Lucinda, additional, Cohen, Graham Lawrence, additional, Rapoport, Bernardo Louis, additional, Ruff, Paul, additional, Lee, Nari, additional, Bae, Woo Kyun, additional, Lee, Hyo Jin, additional, Herranz, Urbano Anido, additional, Grande, Enrique, additional, Alonso Gordoa, Teresa, additional, Guma Padro, Josep, additional, Gauna, Daniel Castellano, additional, Arranz, Jose Angel, additional, Munoz Langa, Jose, additional, Sarrio, Regina Girones, additional, Montesa Pino, Alvaro, additional, Juan Fita, Maria Jose, additional, Su, Yu-Li, additional, Lin, Yung-Chang, additional, Su, Wen-Pin, additional, Shen, Ying-Chun, additional, Chang, Yen-Hwa, additional, Huang, Yi-Hsiu, additional, Sriuranpong, Virote, additional, Chansriwong, Phichai, additional, Srimuninnimit, Vichien, additional, Danchaivijitr, Pongwut, additional, Abali, Huseyin, additional, Yavuz, Sinan, additional, Ozyilkan, Ozgur, additional, Sendur, Mehmet Ali Nahit, additional, Ekenel, Meltem, additional, Ozguroglu, Mustafa, additional, Arslan, Cagatay, additional, Ozdogan, Mustafa, additional, Birtle, Alison, additional, Powles, Thomas, additional, Huddart, Robert, additional, de Santis, Maria, additional, Zarkar, Anjali, additional, Evans, Linda, additional, Hussain, Syed, additional, DiSimone, Christopher, additional, Muina, Antonio F, additional, Schlegel, Peter, additional, Jhangiani, Haresh S, additional, Harrison, Michael, additional, Slater, Dennis E, additional, Wright, David, additional, Percent, Ivor J, additional, Lin, Jianqing, additional, Hwang, Clara, additional, Gupta, Sumati, additional, Bajaj, Madhuri, additional, Galamaga, Robert, additional, Eklund, John, additional, Wallace, James, additional, Shtivelband, Mikhail, additional, Suh, Jason Jung-Gon, additional, Burhani, Nafisa, additional, Eadens, Matthew, additional, Gunturu, Krishna, additional, Burgess, Earle, additional, Wong, John, additional, Chaudhry, Arvind, additional, Van Veldhuizen, Peter, additional, Graff, Stephanie, additional, Thomas, Christian A, additional, Schnadig, Ian D, additional, Carneiro, Benedito, additional, Hussain, Maha, additional, Morgans, Alicia, additional, Fitzharris, John T, additional, Oliff, Ira A, additional, Vuky, Jacqueline, additional, Hauke, Ralph, additional, Baron, Ari, additional, Joshi, Monika, additional, Bolemon, Britt H, additional, Jiang, Peter, additional, Mega, Anthony E, additional, Markus, Maurice, additional, Pfanzelter, Nicklas, additional, Lawler, William Eyre, additional, Cobb, Patrick Wayne, additional, Courtright, Jay G, additional, Jain, Sharad, additional, Doshi, Gurjyot, additional, Gunuganti, Vijay K, additional, Sartor, Oliver Alton, additional, Cole, Scott W, additional, Babiker, Hani, additional, Uchio, Edward M, additional, Drakaki, Alexandra, additional, Mannuel, Heather D, additional, Guancial, Elizabeth, additional, Fung, Chunkit, additional, Charles, Anthony, additional, Amato, Robert J, additional, Arriaga, Yull, additional, Bowman, Isaac, additional, Ades, Steven, additional, Dreicer, Robert, additional, Yu, Evan, additional, Quinn, David I, additional, and Fleming, Mark, additional

Published
2021
Full Text
View/download PDF

15. Outreach: Preliminary safety and efficacy results from a phase 2 study of lisocabtagene maraleucel (liso-cel) in the nonuniversity setting.

Author

Godwin, John E., primary, Mattar, Bassam Ibrahim, additional, Maris, Michael B., additional, Bachier, Carlos R., additional, Stevens, Don A., additional, Hoda, Daanish, additional, Varela, Juan Carlos, additional, Cherry, Mohamad, additional, Fanning, Suzanne R., additional, Essell, James H., additional, Yimer, Habte Aragaw, additional, Courtright, Jay G., additional, Sharman, Jeff Porter, additional, Trede, Nikolaus S., additional, Youssef, Marina, additional, Lymp, James, additional, and Shaughnessy, Paul, additional

Published
2021
Full Text
View/download PDF

16. Outcomes of Treatment with the Chimeric Antigen Receptor (CAR) T Cell Therapy Lisocabtagene Maraleucel (liso-cel) at Nonuniversity Medical Centers (NMCs): Initial Results from the Outreach Study in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Author

Godwin, John, primary, Freytes, Cesar O., additional, Maris, Michael, additional, Stevens, Don A., additional, Hoda, Daanish, additional, Mattar, Bassam, additional, Varela, Juan C., additional, Cherry, Mohamad, additional, Essell, James, additional, Courtright, Jay, additional, Fanning, Suzanne, additional, Yimer, Habte, additional, Trede, Nikolaus S, additional, Youssef, Marina, additional, Lymp, James, additional, and Bachier, Carlos R., additional

Published
2021
Full Text
View/download PDF

17. Debulking Regimens Prior to Initiating Venetoclax Therapy in Untreated Patients with Chronic Lymphocytic Leukemia: Interim Results from a Phase 3b Study

Author

Flinn, Ian W., primary, Andorsky, David, additional, Melear, Jason M., additional, Manda, Sudhir, additional, Anz, Bertrand M., additional, Kolibaba, Kathryn, additional, Yimer, Habte A., additional, Burke, John M., additional, Fanning, Suzanne R., additional, Courtright, Jay, additional, Islas-Ohlmayer, Miguel, additional, Kambhampati, Suman, additional, Jiang, Daniel Dingfeng, additional, Pesko, John C., additional, Vizkelety, Tamas, additional, Sharmokh, Simon, additional, and Sharman, Jeff P, additional

Published
2020
Full Text
View/download PDF

18. CLL-076: Phase 3b Study to Evaluate Debulking Regimens Prior to Initiating Venetoclax Therapy in Untreated Patients with Chronic Lymphocytic Leukemia

Author

Sharman, Jeff, primary, Andorsky, David, additional, Melear, Jason, additional, Manda, Sudhir, additional, III, Bertrand Anz, additional, Yimer, Kathryn Kolibaba Habte, additional, Burke, John, additional, Fanning, Suzanne, additional, Courtright, Jay, additional, Islas-Ohlmayer, Miguel, additional, Kambhampati, Suman, additional, Jiang, Dingfeng, additional, Pesko, John, additional, Vizkelety, Tamas, additional, Sharmokh, Simon, additional, Nielsen, Jacqueline, additional, and Flinn, Ian, additional

Published
2020
Full Text
View/download PDF

20. Debulking Eliminates Need for Hospitalization Prior to Initiating Frontline Venetoclax Therapy in Previously Untreated CLL Patients: A Phase 3b Study

Author

Sharman, Jeff P., primary, Andorsky, David, additional, Melear, Jason M., additional, Manda, Sudhir, additional, Anz, Bertrand M., additional, Kolibaba, Kathryn S., additional, Yimer, Habte A, additional, Burke, John M, additional, Fanning, Suzanne R., additional, Courtright, Jay, additional, Islas-Ohlmayer, Miguel, additional, Kambhampati, Suman, additional, Masud, Abdullah Al, additional, Zimmerman, Todd, additional, Nielsen, Jacqueline, additional, Vizkelety, Tamas, additional, Jiang, Dingfeng, additional, and Flinn, Ian W., additional

Published
2019
Full Text
View/download PDF

21. 225 - Outcomes of Treatment with the Chimeric Antigen Receptor (CAR) T Cell Therapy Lisocabtagene Maraleucel (liso-cel) at Nonuniversity Medical Centers (NMCs): Initial Results from the Outreach Study in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Author

Godwin, John, Freytes, Cesar O., Maris, Michael, Stevens, Don A., Hoda, Daanish, Mattar, Bassam, Varela, Juan C., Cherry, Mohamad, Essell, James, Courtright, Jay, Fanning, Suzanne, Yimer, Habte, Trede, Nikolaus S, Youssef, Marina, Lymp, James, and Bachier, Carlos R.

Published
2021
Full Text
View/download PDF

22. Scalp Cooling Alopecia Prevention trial (SCALP) for patients with early stage breast cancer.

Author

Nangia, Julie R., primary, Wang, Tao, additional, Osborne, Cynthia R. C., additional, Niravath, Polly Ann, additional, Otte, Kristen, additional, Papish, Steven W., additional, Holmes, Frankie Ann, additional, Abraham, Jame, additional, Goldfarb, Shari Beth, additional, Courtright, Jay G., additional, Paxman, Richard, additional, Rude, Mari, additional, Hilsenbeck, Susan G., additional, Osborne, C. Kent, additional, and Rimawi, Mothaffar F., additional

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results